DSM Capital Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$87.2M |
| 2 |
DexCom
DXCM
|
+$80.6M |
| 3 |
Netflix
NFLX
|
+$57.6M |
| 4 |
Dynatrace
DT
|
+$35.6M |
| 5 |
FISV
Fiserv Inc
FISV
|
+$28.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arthur J. Gallagher & Co
AJG
|
+$137M |
| 2 |
Advanced Micro Devices
AMD
|
+$131M |
| 3 |
Arista Networks
ANET
|
+$54M |
| 4 |
Meta Platforms (Facebook)
META
|
+$38.3M |
| 5 |
Microsoft
MSFT
|
+$37.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 58.57% |
| 2 | Communication Services | 15.69% |
| 3 | Consumer Discretionary | 10.52% |
| 4 | Industrials | 5.69% |
| 5 | Healthcare | 5.32% |
Similar funds
DSM Capital Partners's Q2 2025 Portfolio in Review
As of Q2 2025, DSM Capital Partners held 41 positions worth $6.77B, up 18% from $5.72B the previous quarter. Its ten largest holdings account for 72% of the portfolio.
DSM Capital Partners withdrew a net $275M in Q2 2025, closing 2 positions and reducing 26 holdings. Its most notable exit was Arthur J. Gallagher & Co, an estimated $137M position sold in full.
By sector, the portfolio is most concentrated in Technology at 59% of assets, up from 56% a quarter earlier, followed by Communication Services and Consumer Discretionary.
Against the trend, DSM Capital Partners opened a new position in Boston Scientific worth $307K.
- DSM Capital Partners's largest Q2 2025 buy was Boston Scientific: 2,858 shares worth $307K.
- DSM Capital Partners added most to Broadcom in Q2 2025, an estimated $87.2M increase.
- DSM Capital Partners's biggest Q2 2025 reduction was Arista Networks, cutting an estimated $54M.
- DSM Capital Partners fully exited Arthur J. Gallagher & Co in Q2 2025, selling an estimated $137M.
- DSM Capital Partners's ten largest holdings make up 72% of its $6.77B portfolio in Q2 2025.
- DSM Capital Partners opened 2 new positions and closed 2 in Q2 2025.
- DSM Capital Partners's portfolio value rose 18% quarter-over-quarter to $6.77B.
Based on DSM Capital Partners's 13F filing for Q2 2025, filed 24 Jul 2025.